SGLT2 Inhibitors are Associated With Reduced CV Disease in Type 2 Diabetes

Описание к видео SGLT2 Inhibitors are Associated With Reduced CV Disease in Type 2 Diabetes

Dr. Wendy Wang, a Post-Doctoral Fellow at the University of Minnesota, School of Public Health, in Minneapolis, MN, reviews her article appearing in the July 2023 issue of Mayo Clinic Proceedings, where examining data from the MarketScan Database between 2013 and 2019, she found the class of SGLT2 inhibitor therapies were associated with a lower risk of cardiovascular disease among patients with type 2 diabetes compared to other second line diabetes therapy options. Available at: https://mayocl.in/3ooALwA

Комментарии

Информация по комментариям в разработке

Похожие видео